The Current Clinical Trial Landscape for Hidradenitis Suppurativa : A Narrative Review
© 2023. The Author(s)..
Hidradenitis suppurativa (HS) is a skin disease resulting from chronic, recurrent inflammation around hair follicles, characterized by proinflammatory cytokines such as IL-1, IL-17, IL-23, and TNF-α. While adalimumab, a TNF-α targeting human IgG monoclonal antibody, is the only approved treatment for HS, there are many other therapies being investigated now targeting other key players in inflammatory pathways such as the cytokines listed above, C5a in the complement pathway, and Janus kinase (JAK). This review discusses current clinical trials for biologics and small molecules, procedures, and wound dressings undergoing study in hidradenitis suppurativa.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Dermatology and therapy - 13(2023), 7 vom: 01. Juli, Seite 1391-1407 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hunt, Amanda [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clinical trials |
|---|
| Anmerkungen: |
Date Revised 02.07.2023 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1007/s13555-023-00935-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357637461 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357637461 | ||
| 003 | DE-627 | ||
| 005 | 20231226073027.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s13555-023-00935-x |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1192.xml |
| 035 | |a (DE-627)NLM357637461 | ||
| 035 | |a (NLM)37261652 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hunt, Amanda |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Current Clinical Trial Landscape for Hidradenitis Suppurativa |b A Narrative Review |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 02.07.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a Hidradenitis suppurativa (HS) is a skin disease resulting from chronic, recurrent inflammation around hair follicles, characterized by proinflammatory cytokines such as IL-1, IL-17, IL-23, and TNF-α. While adalimumab, a TNF-α targeting human IgG monoclonal antibody, is the only approved treatment for HS, there are many other therapies being investigated now targeting other key players in inflammatory pathways such as the cytokines listed above, C5a in the complement pathway, and Janus kinase (JAK). This review discusses current clinical trials for biologics and small molecules, procedures, and wound dressings undergoing study in hidradenitis suppurativa | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Clinical trials | |
| 650 | 4 | |a Hidradenitis suppurativa | |
| 650 | 4 | |a Treatment | |
| 700 | 1 | |a Qian, Victoria |e verfasserin |4 aut | |
| 700 | 1 | |a Olds, Hailey |e verfasserin |4 aut | |
| 700 | 1 | |a Daveluy, Steven |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Dermatology and therapy |d 2011 |g 13(2023), 7 vom: 01. Juli, Seite 1391-1407 |w (DE-627)NLM221084762 |x 2193-8210 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2023 |g number:7 |g day:01 |g month:07 |g pages:1391-1407 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s13555-023-00935-x |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2023 |e 7 |b 01 |c 07 |h 1391-1407 | ||